<DOC>
	<DOCNO>NCT02235909</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety study drug relative active comparator losartan class drug approve use pediatric population age 6 year old . Approximately 260 subject participate 6-week , double-blind , randomized , treatment phase , follow 2-week , double-blind , randomized placebo-controlled withdrawal phase . This study also include 44-week , open-label extension ( OL Phase ) subject receive AZM antihypertensive medication ( need ) order reach optimal blood pressure . Blood pressure assess clinic throughout study , subject may also participate 24-hour ambulatory blood pressure monitoring ( ABPM ) procedure baseline , end DB Phase end OL Phase .</brief_summary>
	<brief_title>An Efficacy Safety Study Children 6 Less Than 18 Years Age With Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>The subject hypertension ( primary secondary ) define clinic Seated Diastolic BP ≥95th percentile ( age , gender , height ) ≥90th percentile ( age , gender , height ) chronic renal disease , diabetes , heart failure hypertensive target organ damage present 1 . If currently treat : The subject document historical diagnosis hypertension AND postwashout clinic Seated Diastolic BP meeting criterion Day 1 ( Day 1 subject participate Ambulatory Blood Pressure Monitoring ) 2 . If currently untreated : The subject elevate Seated Diastolic BP meeting criterion 3 separate occasion Randomization , include Day 1 ( Day 1 subject participate Ambulatory Blood Pressure Monitoring ) The subject male female age 6 &lt; 18 year Baseline weigh least 25 kg The subject agree continue previously implement nonpharmacological life style modification begin prior Screening . Note : For subject participate weight loss program , weight maintenance The subject clinic Seated Diastolic BP great 15 mm Hg and/or Seated Diastolic BP great 10 mm Hg 99th percentile age , gender , height confirm average ( arithmetic mean ) 3 serial clinic seat BP measurement Screening/Visit 1 The subject diagnosis malignant accelerate hypertension The subject currently treat 2 antihypertensive agent The subject parent/legal guardian willing subject 's previous antihypertensive medication stop The subject participate intensive , active weightloss phase weightloss program within 30 day prior Screening/Visit 1 The subject following : severe renal impairment ( eGFR &lt; 30 mL/min/1.73 m2 Schwartz formula ) ; currently undergo dialysis treatment ; renovascular disease affect kidney solitary kidney ; severe nephrotic syndrome remission ; serum albumin &lt; 2.5 g/dL The subject history clinical manifestation severe cardiovascular , hepatobiliary , gastrointestinal , endocrinemetabolic ( e.g. , hyperthyroidism , Cushing 's syndrome ) , hematologic , immunologic , genitourinary , psychiatric disease , cancer , and/or condition would interfere health status subject study participation , would jeopardize study integrity opinion investigator The subject suffering uncorrected coarctation aorta , hemodynamically significant leave ventricular outflow tract obstruction due eg , aortic valvular disease , likely undergo procedure know affect blood pressure ( eg , repair arterial anomaly ) course study The subject poorly control diabetic define glycosylated hemoglobin value &gt; 8.5 % Screening/Visit 1 The subject hyperkalemia define central laboratory 's normal reference range pertinent electrolyte disorder Screening/Visit</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pediatric Hypertension</keyword>
	<keyword>High Blood Pressure</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Primary Hypertension</keyword>
	<keyword>Secondary Hypertension</keyword>
</DOC>